Log In
BCIQ
Print this Print this
 

hydrocodone bitartrate ER, Hysingla ER

  Manage Alerts
Collapse Summary General Information
Company Purdue Pharma L.P.
DescriptionOnce-daily, extended-release (ER) formulation of hydrocodone bitartrate formulated with an abuse-deterrent technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationPain
Indication DetailsTreat chronic pain; Treat moderate to severe chronic low back pain
Regulatory Designation U.S. - Priority Review (Treat chronic pain)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$10.0M

$5.0M

$5.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/31/2014

$10.0M

$5.0M

$5.0M

Get a free BioCentury trial today